Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
General Info
Time period covered
January, 2011 - December, 2011
Data type
Scientific literature
Citation
Journal
N Engl J Med
Pages
1500-9
Publication year
2015
Suggested citation
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16): 1500-9.